With TRex Bio and Retension Pharmaceuticals through the IPO window, City Therapeutics is gearing up for its own public debut, about four months after raising a $99.5-million series B The drugmaker on Friday proposed to sell 9.7 million shares at a range of $17 to $19 apiece. At the midpoint, City would raise $175 million; if the offering prices at the high end, its market valuation could near $1 billion. Two other biotechs are waiting in the wings with City: Iambic Therapeutics, which is eyein

Medincell (Euronext: MEDCL) achieves major milestone with the announcement by its partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd, of the U.S. Food and Drug Administration (FDA) approval of WELTRUZA™ (olanzapine) for extended-release injectable suspension, as the first and only once-monthly subcutaneouslong-acting injectable (LAI) formulation of olanzapine for adults with schizophrenia that can help support stabilization for people living with schizophrenia.

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile Oct. 9, 2026 -- Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric pati

With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure. While awaiting a decision from the FDA on its novel non-opioid pain treatment, Viatris has agreed to buy Pacira BioSciences for $1.65 billion to accelerate its expansion into non-opioid pain therapy. Pacira sells Exparel and Zilretta, pain treatments that generated sales of $587 million and $121 million, respectively, in the s

October 8, 2026, Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop the study for futility following an interim analysis. The IDMC concluded th

Combined with its Seed round of $8.5M, the company has raised more than $16.5M in support of its activities. Vinci Pharmaceuticals closed an $8+ million Series A financing round to support manufacturing, testing/release activities and first-in-human studies of its EPIPLANT™ drug delivery platform. EPIPLANT™, the company's proprietary, episcleral sustained-release drug delivery platform is designed to address limitations of intraocular injections. A Phase 1/2a clinical study is scheduled for 2027

On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and ped

Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer HCW11-018b is Company’s lead candidate in its second-generation T-Cell Engager Program constructed using proprietary non-FC based TRBC platform technology Manufacturing of cGMP material for clinical trials is underway IND application remains on track to be filed in 1H 2027 Oct. 09, 2026 -- HCW Biologics Inc. (the “Company” or “HCW

First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer, including metastatic uveal melanoma (mUM) Publication of the peer-reviewed papers comes as iOnctura awaits readouts from its two fully-enrolled, randomize

Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular disease, and Synfini, Inc., an agile AI foundry for small-molecule drug discovery, today announced results from a research collaboration that has produced a validated-quality lead candidate directed at MSH3, a gene increasingly understood to drive the somatic repeat expansion that paces the progression of Huntington’s disease. The companies reached the milestone in a matter of weeks. Industry benchma